New AI test can predict which men will benefit from prostate cancer drug

Doctors have developed an artificial intelligence tool that can predict which men with prostate cancer will benefit from a drug that halves the risk of dying. Abiraterone has been described as a "gamechanger" treatment for the disease, which is the most common form of cancer in men in more than 100 countries. It has already helped hundreds of thousands with advanced prostate cancer to live longer. But some countries, including England, have stopped short of offering the "spectacular" drug more widely to men whose disease has not spread. Now a team from the US, UK and Switzerland have built an AI test that shows which men would most likely benefit from abiraterone. The "exciting" breakthrough will enable healthcare systems to roll out the drug to more men, and spare others unnecessary treatment.